Moh Tadayyon
Co-founder Apeikon Therapeutics
Seminars
Thursday 3rd December 2026
Insight Exchange – Building an End-to-End Development Strategy That Delivers Better Decisions
3:20 pm
- Where do development programmes most commonly break down between discovery, translational, clinical, and external partners?
- How early should CROs, translational scientists, and pharmacology teams be involved in model selection decisions?
- What distinguishes a strategic partner from a service provider when generating decision-grade data?
- How can organisations balance speed, cost, scientific rigour, and translational confidence throughout development?
- Audience Q&As
Thursday 3rd December 2026
Evidence – Building Integrated Development Strategies to Improve Development Time-lines & Reduce Late-Stage Risks
2:40 pm
- Reducing late-stage risk by integrating decision making across biology, pharmacology and regulatory functions
- Aligning model selection, biomarker strategy, PK/PD understanding, formulation and regulatory planning earlier in development
- Updating ‘traditional’ organisation structures to improve communication between discovery, translational, and clinical and regulatory functions
